☰

Melissa D. Landis, Ph.D. - Publications

Affiliations: 
2006 Case Western Reserve University, Cleveland Heights, OH, United States 
Area:
Molecular Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Sahni JM, Gayle SS, Bonk KLW, Vite LC, Yori JL, Webb B, Ramos EK, Seachrist DD, Landis MD, Chang JC, Bradner JE, Keri RA. Correction: Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of aurora kinases. The Journal of Biological Chemistry. 295: 9266. PMID 33516519 DOI: 10.1074/jbc.AAC120.014699  0.754
2020 Sahni JM, Gayle SS, Bonk KLW, Vite LC, Yori JL, Webb B, Ramos EK, Seachrist DD, Landis MD, Chang JC, Bradner JE, Keri RA. Correction: Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of aurora kinases. The Journal of Biological Chemistry. 295: 9266. PMID 32620694 DOI: 10.1074/jbc.AAC120.014699  0.754
2017 Liu Y, Choi DS, Sheng J, Ensor JE, Liang DH, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A, Cong Y, Wong H, Qian W, Li Z, Granados-Principal S, ... ... Landis MD, et al. HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway. Stem Cell Reports. PMID 29249663 DOI: 10.1016/J.Stemcr.2017.11.010  0.589
2016 Sahni JM, Gayle SS, Weber-Bonk KL, Cuellar Vite L, Yori JL, Webb B, Ramos EK, Seachrist DD, Landis MD, Chang JC, Bradner JE, Keri RA. Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of Aurora kinases. The Journal of Biological Chemistry. PMID 27650498 DOI: 10.1074/Jbc.M116.738666  0.753
2016 Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, et al. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Science Translational Medicine. 8: 334ra53. PMID 27075627 DOI: 10.1126/Scitranslmed.Aad3001  0.611
2016 Tanei T, Choi DS, Rodriguez AA, Liang DH, Dobrolecki L, Ghosh M, Landis MD, Chang JC. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells. Breast Cancer Research : Bcr. 18: 6. PMID 26757880 DOI: 10.1186/s13058-015-0662-4  0.496
2015 Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, Zhao H, Landis MD, Dave B, Gross SS, Chang JC. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Breast Cancer Research : Bcr. 17: 25. PMID 25849745 DOI: 10.1186/S13058-015-0527-X  0.563
2015 Ferrati S, Nicolov E, Bansal S, Hosali S, Landis M, Grattoni A. Docetaxel/2-Hydroxypropyl β-Cyclodextrin Inclusion Complex Increases Docetaxel Solubility and Release from a Nanochannel Drug Delivery System. Current Drug Targets. PMID 25706254  0.377
2015 Bharadwaj U, Eckols TK, Kolosov M, Kasembeli MM, Adam A, Torres D, Zhang X, Dobrolecki LE, Wei W, Lewis MT, Dave B, Chang JC, Landis MD, Creighton CJ, Mancini MA, et al. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene. 34: 1341-53. PMID 24681959 DOI: 10.1038/Onc.2014.72  0.625
2014 Choi DS, Blanco E, Kim YS, Rodriguez AA, Zhao H, Huang TH, Chen CL, Jin G, Landis MD, Burey LA, Qian W, Granados SM, Dave B, Wong HH, Ferrari M, et al. Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1. Stem Cells (Dayton, Ohio). 32: 2309-23. PMID 24809620 DOI: 10.1002/Stem.1746  0.349
2014 Sahin O, Wang Q, Brady SW, Ellis K, Wang H, Chang CC, Zhang Q, Priya P, Zhu R, Wong ST, Landis MD, Muller WJ, Esteva FJ, Chang J, Yu D. Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Research. 24: 542-59. PMID 24675532 DOI: 10.1038/Cr.2014.37  0.423
2014 Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, Tam WL, Ni M, Chen Y, Mai J, Shen H, Hu DZ, Adoro S, Hu B, ... ... Landis MD, et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature. 508: 103-7. PMID 24670641 DOI: 10.1038/Nature13119  0.599
2014 Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, Hong S, Adams A, D'Angelo R, Ginestier C, Charafe-Jauffret E, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports. 2: 78-91. PMID 24511467 DOI: 10.1016/J.Stemcr.2013.11.009  0.442
2013 van de Ven AL, Abdollahi B, Martinez CJ, Burey LA, Landis MD, Chang JC, Ferrari M, Frieboes HB. Modeling of nanotherapeutics delivery based on tumor perfusion. New Journal of Physics. 15: 55004. PMID 24039540 DOI: 10.1088/1367-2630/15/5/055004  0.311
2013 Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JC. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Research : Bcr. 15: R77. PMID 24008095 DOI: 10.1186/Bcr3471  0.426
2013 Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Research. 73: 4885-97. PMID 23737486 DOI: 10.1158/0008-5472.Can-12-4081  0.466
2013 Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1512-24. PMID 23340294 DOI: 10.1158/1078-0432.CCR-11-3326  0.44
2013 Landis MD, Lehmann BD, Pietenpol JA, Chang JC. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Research : Bcr. 15: 201. PMID 23339383 DOI: 10.1186/Bcr3355  0.598
2012 Zhang W, Kai K, Choi DS, Iwamoto T, Nguyen YH, Wong H, Landis MD, Ueno NT, Chang J, Qin L. Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America. 109: 18707-12. PMID 23112172 DOI: 10.1073/Pnas.1209893109  0.382
2012 Dave B, Landis MD, Tweardy DJ, Chang JC, Dobrolecki LE, Wu MF, Zhang X, Westbrook TF, Hilsenbeck SG, Liu D, Lewis MT. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. Plos One. 7: e30207. PMID 22879872 DOI: 10.1371/Journal.Pone.0030207  0.524
2012 Creighton CJ, Sada YH, Zhang Y, Tsimelzon A, Wong H, Dave B, Landis MD, Bear HD, Rodriguez A, Chang JC. A gene transcription signature of obesity in breast cancer. Breast Cancer Research and Treatment. 132: 993-1000. PMID 21750966 DOI: 10.1007/S10549-011-1595-Y  0.381
2010 Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, Rodriguez AA, Landis MD, Lucci A, Ueno NT, Robertson F, Xu W, Lacerda L, Buchholz TA, Cristofanilli M, et al. Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Molecular Cancer. 9: 180. PMID 20615238 DOI: 10.1186/1476-4598-9-180  0.311
2009 Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America. 106: 13820-5. PMID 19666588 DOI: 10.1073/Pnas.0905718106  0.399
2009 Montañez-Wiscovich ME, Seachrist DD, Landis MD, Visvader J, Andersen B, Keri RA. LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression. Oncogene. 28: 3608-18. PMID 19648968 DOI: 10.1038/Onc.2009.221  0.77
2008 Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Research. 68: 4674-82. PMID 18559513 DOI: 10.1158/0008-5472.Can-07-6353  0.366
2008 Milliken EL, Lozada KL, Johnson E, Landis MD, Seachrist DD, Whitten I, Sutton AL, Abdul-Karim FW, Keri RA. Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer. Oncogene. 27: 1759-66. PMID 17891171 DOI: 10.1038/Sj.Onc.1210815  0.761
2007 Mosley JD, Poirier JT, Seachrist DD, Landis MD, Keri RA. Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer. Molecular Cancer Therapeutics. 6: 2188-97. PMID 17699716 DOI: 10.1158/1535-7163.Mct-07-0235  0.776
2006 Landis MD, Seachrist DD, Abdul-Karim FW, Keri RA. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors. Oncogene. 25: 3325-34. PMID 16434967 DOI: 10.1038/Sj.Onc.1209365  0.695
2005 Landis MD, Seachrist DD, Montañez-Wiscovich ME, Danielpour D, Keri RA. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. Oncogene. 24: 5173-90. PMID 15897883 DOI: 10.1038/Sj.Onc.1208712  0.684
2002 Milliken EL, Ameduri RK, Landis MD, Behrooz A, Abdul-Karim FW, Keri RA. Ovarian hyperstimulation by LH leads to mammary gland hyperplasia and cancer predisposition in transgenic mice. Endocrinology. 143: 3671-80. PMID 12193583 DOI: 10.1210/En.2002-220228  0.758
Show low-probability matches.